Sareum Announces CHK1 inhibitor CCT245737 Approval for Phase 1 Clinica


Sign up online today & collaborate

or click here to find out more

Sareum Announces CHK1 inhibitor CCT245737 Approval for Phase 1 Clinical Trials


Cambridge, UK – Sareum Holdings plc (AIM:SAR), the specialist cancer drug discovery and development company, is pleased to announce that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved the Clinical Trial Applications (CTAs) for CHK1 inhibitor drug candidate CCT245737.

Subject to final NHS approval, clinical trials are expected to begin in Q2 2016. Two Phase I clinical trials in cancer patients are planned, in collaboration with co-development partners, the CRT Pioneer Fund. One trial will use CCT245737 in combination with standard-of-care chemotherapy and will ultimately target lung and pancreatic cancer patients. The other trial will use CCT245737 as a single anti-cancer agent and will initially target various cancers.

As noted in its announcement of 1 February 2016, Sareum satisfied a financial commitment of £797,500 to the funding of these trials in December 2015, and the submission of the Clinical Trial Applications triggered the receipt of a £200,000 success milestone payment from Cancer Research Technology Ltd to Sareum.

Sareum’s CEO, Dr Tim Mitchell, commented: “This approval for CCT245737 is another significant milestone along its path to being the first from our development pipeline to enter clinical trials.”


© Catalyst Innovation Portal 2019